2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
3 412
Myynti
Määrä
8 151
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 200 | SSWM | NON | ||
| 1 370 | SSWM | NON | ||
| 1 370 | SSWM | NON | ||
| 6 200 | SSWM | NON | ||
| 5 808 | NON | SHB |
Ylin
1,105VWAP
Alin
1,04VaihtoMäärä
0 26 693
VWAP
Ylin
1,105Alin
1,04VaihtoMäärä
0 26 693
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 17 140 | 0 | +17 140 | 0 |
| Nordnet Bank AB | 0 | 17 140 | −17 140 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 0 | 17 140 | −17 140 | 0 |
| SSW Market Making GmbH | 17 140 | 0 | +17 140 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 30.1. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 31.7.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 | ||
2024 Q4 -tulosraportti 30.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
3 päivää sitten3 päivää sittenMDR Certification for Raypilot System Micropos Medical has received both MDR and UKCA certification for the Raypilot System. This confirms that the Raypilot System is now fully compliant with the EU Medical Device Regulation MDR 2017/745 as well as UK MDR 2002 for medical devices. Achieving this certification has been a comprehensive effort that required strong commitment and significant resources from the entire organization. Through close collaboration, meticulous documentation, and a shared focus, we have successfully met the demanding regulatory requirements. “Obtaining MDR certification is an extremely important milestone for us. It is proof that our products are safe and meet the strict standards required for medical devices. This certification is highly meaningful for us as a company, for our customers, and most importantly for patient safety. It also enables us to continue improving the product and expand further,” says Hanna Syrén, COO and QA/RA at Micropos Medical.
·30.1.Unfortunately, almost all loss-making companies are struggling. Natural and nyem. perhaps it wasn't appropriate to take right now - but all companies need money and literally eat money. Often the main owner has had to pay significantly for stock market downturns over the years. The problem is no direct sales yet.- ·29.1.Good news the day before the report is not always such good news. Quite certain that there will be news about NE tomorrow, but I have expected that and in that case, it will be no surprise. But then...
- ·9.12.2025Answer to CoPilot question: Direct Answer: The two U.S. clinics scheduled for Raypilot® System installations in Q4 2025 have not been publicly named in Micropos Medical’s Q3 2025 report. What is confirmed is that they are described as “two well‑renowned clinics in the USA” and that the installations are being carried out in collaboration with Varian Medical Systems, the world’s leading manufacturer of linear accelerators. 🔍 What We Know Decision taken: Micropos Medical announced in its Q3 2025 interim report that Raypilot® will be installed at two prestigious U.S. clinics. Timeline: Installations are scheduled for Q4 2025. Partnership: The collaboration with Varian Medical Systems strengthens credibility and marketing in the U.S. market. Strategic importance: These installations are part of Micropos’s push to expand Augmented SBRT adoption in North America, where validation from top clinics carries significant weight. 📊 Context Earlier U.S. adoption: In August 2024, Micropos announced its first U.S. order at the Medical University of South Carolina (MUSC), where Dr. David Marshall highlighted Raypilot’s ability to improve accuracy and reduce toxicity. Momentum building: The Q3 2025 report signals that Micropos is moving beyond pilot installations into larger, more influential clinics, supported by Varian’s integration capabilities. Market impact: If these two unnamed clinics report positive outcomes, it could accelerate adoption across other U.S. cancer centers. 🎯 Bottom Line The exact names of the two U.S. clinics have not yet been disclosed publicly, but the installations are confirmed for Q4 2025 and are strategically significant because they involve Varian Medical Systems. This partnership positions Raypilot® for broader U.S. adoption, following the earlier MUSC installation. 👉 Once Micropos releases its Q4 2025 report, the names of the clinics are likely to be revealed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3 päivää sitten3 päivää sittenMDR Certification for Raypilot System Micropos Medical has received both MDR and UKCA certification for the Raypilot System. This confirms that the Raypilot System is now fully compliant with the EU Medical Device Regulation MDR 2017/745 as well as UK MDR 2002 for medical devices. Achieving this certification has been a comprehensive effort that required strong commitment and significant resources from the entire organization. Through close collaboration, meticulous documentation, and a shared focus, we have successfully met the demanding regulatory requirements. “Obtaining MDR certification is an extremely important milestone for us. It is proof that our products are safe and meet the strict standards required for medical devices. This certification is highly meaningful for us as a company, for our customers, and most importantly for patient safety. It also enables us to continue improving the product and expand further,” says Hanna Syrén, COO and QA/RA at Micropos Medical.
- ·30.1.Unfortunately, almost all loss-making companies are struggling. Natural and nyem. perhaps it wasn't appropriate to take right now - but all companies need money and literally eat money. Often the main owner has had to pay significantly for stock market downturns over the years. The problem is no direct sales yet.
- ·29.1.Good news the day before the report is not always such good news. Quite certain that there will be news about NE tomorrow, but I have expected that and in that case, it will be no surprise. But then...
- ·9.12.2025Answer to CoPilot question: Direct Answer: The two U.S. clinics scheduled for Raypilot® System installations in Q4 2025 have not been publicly named in Micropos Medical’s Q3 2025 report. What is confirmed is that they are described as “two well‑renowned clinics in the USA” and that the installations are being carried out in collaboration with Varian Medical Systems, the world’s leading manufacturer of linear accelerators. 🔍 What We Know Decision taken: Micropos Medical announced in its Q3 2025 interim report that Raypilot® will be installed at two prestigious U.S. clinics. Timeline: Installations are scheduled for Q4 2025. Partnership: The collaboration with Varian Medical Systems strengthens credibility and marketing in the U.S. market. Strategic importance: These installations are part of Micropos’s push to expand Augmented SBRT adoption in North America, where validation from top clinics carries significant weight. 📊 Context Earlier U.S. adoption: In August 2024, Micropos announced its first U.S. order at the Medical University of South Carolina (MUSC), where Dr. David Marshall highlighted Raypilot’s ability to improve accuracy and reduce toxicity. Momentum building: The Q3 2025 report signals that Micropos is moving beyond pilot installations into larger, more influential clinics, supported by Varian’s integration capabilities. Market impact: If these two unnamed clinics report positive outcomes, it could accelerate adoption across other U.S. cancer centers. 🎯 Bottom Line The exact names of the two U.S. clinics have not yet been disclosed publicly, but the installations are confirmed for Q4 2025 and are strategically significant because they involve Varian Medical Systems. This partnership positions Raypilot® for broader U.S. adoption, following the earlier MUSC installation. 👉 Once Micropos releases its Q4 2025 report, the names of the clinics are likely to be revealed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
3 412
Myynti
Määrä
8 151
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 200 | SSWM | NON | ||
| 1 370 | SSWM | NON | ||
| 1 370 | SSWM | NON | ||
| 6 200 | SSWM | NON | ||
| 5 808 | NON | SHB |
Ylin
1,105VWAP
Alin
1,04VaihtoMäärä
0 26 693
VWAP
Ylin
1,105Alin
1,04VaihtoMäärä
0 26 693
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 17 140 | 0 | +17 140 | 0 |
| Nordnet Bank AB | 0 | 17 140 | −17 140 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 0 | 17 140 | −17 140 | 0 |
| SSW Market Making GmbH | 17 140 | 0 | +17 140 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 30.1. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 31.7.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 | ||
2024 Q4 -tulosraportti 30.1.2025 |
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 30.1. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 31.7.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 | ||
2024 Q4 -tulosraportti 30.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3 päivää sitten3 päivää sittenMDR Certification for Raypilot System Micropos Medical has received both MDR and UKCA certification for the Raypilot System. This confirms that the Raypilot System is now fully compliant with the EU Medical Device Regulation MDR 2017/745 as well as UK MDR 2002 for medical devices. Achieving this certification has been a comprehensive effort that required strong commitment and significant resources from the entire organization. Through close collaboration, meticulous documentation, and a shared focus, we have successfully met the demanding regulatory requirements. “Obtaining MDR certification is an extremely important milestone for us. It is proof that our products are safe and meet the strict standards required for medical devices. This certification is highly meaningful for us as a company, for our customers, and most importantly for patient safety. It also enables us to continue improving the product and expand further,” says Hanna Syrén, COO and QA/RA at Micropos Medical.
- ·30.1.Unfortunately, almost all loss-making companies are struggling. Natural and nyem. perhaps it wasn't appropriate to take right now - but all companies need money and literally eat money. Often the main owner has had to pay significantly for stock market downturns over the years. The problem is no direct sales yet.
- ·29.1.Good news the day before the report is not always such good news. Quite certain that there will be news about NE tomorrow, but I have expected that and in that case, it will be no surprise. But then...
- ·9.12.2025Answer to CoPilot question: Direct Answer: The two U.S. clinics scheduled for Raypilot® System installations in Q4 2025 have not been publicly named in Micropos Medical’s Q3 2025 report. What is confirmed is that they are described as “two well‑renowned clinics in the USA” and that the installations are being carried out in collaboration with Varian Medical Systems, the world’s leading manufacturer of linear accelerators. 🔍 What We Know Decision taken: Micropos Medical announced in its Q3 2025 interim report that Raypilot® will be installed at two prestigious U.S. clinics. Timeline: Installations are scheduled for Q4 2025. Partnership: The collaboration with Varian Medical Systems strengthens credibility and marketing in the U.S. market. Strategic importance: These installations are part of Micropos’s push to expand Augmented SBRT adoption in North America, where validation from top clinics carries significant weight. 📊 Context Earlier U.S. adoption: In August 2024, Micropos announced its first U.S. order at the Medical University of South Carolina (MUSC), where Dr. David Marshall highlighted Raypilot’s ability to improve accuracy and reduce toxicity. Momentum building: The Q3 2025 report signals that Micropos is moving beyond pilot installations into larger, more influential clinics, supported by Varian’s integration capabilities. Market impact: If these two unnamed clinics report positive outcomes, it could accelerate adoption across other U.S. cancer centers. 🎯 Bottom Line The exact names of the two U.S. clinics have not yet been disclosed publicly, but the installations are confirmed for Q4 2025 and are strategically significant because they involve Varian Medical Systems. This partnership positions Raypilot® for broader U.S. adoption, following the earlier MUSC installation. 👉 Once Micropos releases its Q4 2025 report, the names of the clinics are likely to be revealed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
3 412
Myynti
Määrä
8 151
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 200 | SSWM | NON | ||
| 1 370 | SSWM | NON | ||
| 1 370 | SSWM | NON | ||
| 6 200 | SSWM | NON | ||
| 5 808 | NON | SHB |
Ylin
1,105VWAP
Alin
1,04VaihtoMäärä
0 26 693
VWAP
Ylin
1,105Alin
1,04VaihtoMäärä
0 26 693
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 17 140 | 0 | +17 140 | 0 |
| Nordnet Bank AB | 0 | 17 140 | −17 140 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 0 | 17 140 | −17 140 | 0 |
| SSW Market Making GmbH | 17 140 | 0 | +17 140 | 0 |